Genetic polymorphisms in the carbonyl reductase 3 gene <i>CBR3</i> and the NAD(P)H:quinone oxidoreductase 1 gene <i>NQO1</i> in patients who developed anthracycline‐related congestive heart failure after childhood cancer

Abstract

The functional CBR3 V244M polymorphism may have an impact on the risk of anthracycline-related CHF among childhood cancer survivors by modulating the intracardiac formation of cardiotoxic anthracycline alcohol metabolites. Larger confirmatory case-control studies are warranted.